STOCK MARKET BSE NSE

Trying to bring Sputnik M vaccine for adolescents to India: Dr Reddy's

RDIF last month said it has applied for the registration of Sputnik M, to the Indian regulator for approval.

Published: 29th January 2022 10:31 AM  |   Last Updated: 29th January 2022 10:31 AM   |  A+A-

Sputnik V coronavirus vaccine. (File Photo | AP)

Sputnik V coronavirus vaccine. (File Photo | AP)

By PTI

HYDERABAD: Dr Reddy's Laboratories on Friday said it is in discussions with the Indian drug regulator to bring Russia's Sputnik M, a Covid vaccine for the 12 to18-year-old categories, to India.

Addressing a press conference after announcing the company's Q3 results, a senior executive of the drugmaker said, Phase 3 clinical trial data of Russia's single-dose Covid vaccine Sputnik Light has been submitted to the regulator and is awaiting approval.

Deepak Sapra CEO, API, and Services Dr Reddy's, also said the company is fully geared to make Molnupiravir, a Covid drug both API and Formulations, at its facilities, even as it approached the World Health organization for the prequalification of the drug.

"Sputnik M is a sputnik for adolescents. In Russia, Sputnik M has been given approval by the regulator for children in the 12 to 18 years old group. The same data has been made available here. We are in the process of translating the data and we will be having a conversation with the regulator on this data within the next few months," Sapra told reporters.

He further said the company may probably conduct another round of clinical trials in India if the Indian regulator says so. 

ALSO READ: Govt allows export of Russian COVID vaccine Sputnik Light manufactured in India by Hetero Biopharma

Russian Direct Investment Fund (RDIF) last month said it has applied for the registration of Sputnik M, to the Indian regulator for approval. The sovereign wealth fund said Russia's Health Ministry registered Sputnik M on November 24, 2021.

Replying to a query, he said the clinical trials for the Sputnik Light in India are over and the data was submitted to the Drug Controller General of India. "It has demonstrated efficacy which is consistent and in line with the result that we have seen in the global trials which we have conducted in Russia. What we conducted in India is safety and immunogenicity studies," Sapra said.

On Molnupiravir, the official said in this current wave Omicron is the dominant variant and it has seen relatively lower hospitalizations.

However, the company will continue to be ready for the COVID-19 drug to be made available for India and 103 countries for which it has rights.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp